Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 15 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

86%

6 of 7 completed with results

Key Signals

6 with results100% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (2)
P 1 (1)
P 2 (11)

Trial Status

Completed7
Recruiting4
Unknown2
Active Not Recruiting1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT02180867Phase 2Active Not Recruiting

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

NCT06638931Phase 2Recruiting

Agnostic Therapy in Rare Solid Tumors

NCT06387485Not ApplicableRecruiting

A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning

NCT06849986Phase 2Recruiting

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

NCT06277154Phase 2Recruiting

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

NCT06662734CompletedPrimary

Infantile Versus Adult-type Fibrosarcoma and the Risk of Multiple Primary Malignancies

NCT06526897Not ApplicableNot Yet Recruiting

Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma

NCT02584309Phase 2Completed

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

NCT03989596Phase 2Unknown

Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas

NCT03651375Phase 2Unknown

Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall

NCT01962103Phase 1Completed

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

NCT00356031Phase 2Completed

Bevacizumab and Radiation Therapy for Sarcomas

NCT00503295Phase 2Completed

Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung

NCT00141765Phase 2Completed

Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers

NCT00400569Phase 2Completed

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

Showing all 15 trials

Research Network

Activity Timeline